Nanobiotix S.A. (EPA:NANO)
2.905
-0.035 (-1.19%)
Apr 24, 2025, 5:35 PM CET
Nanobiotix Revenue
In the year 2024, Nanobiotix had annual revenue of -7.19M EUR, down -119.86%. Nanobiotix had revenue of -16.48M in the half year ending December 31, 2024, a decrease of -578.07%.
Revenue
-7.19M
Revenue Growth
-119.86%
P/S Ratio
-19.15
Revenue / Employee
-66.57K
Employees
108
Market Cap
137.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sanofi | 44.29B |
Sartorius Stedim Biotech | 2.86B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.40B |
emeis Société anonyme | 5.64B |
Nanobiotix News
- 21 days ago - Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Nanobiotix GAAP EPS of -€1.44 - Seeking Alpha
- 22 days ago - NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 24 days ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 4 weeks ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 5 weeks ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 5 weeks ago - Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden - Benzinga
- 5 weeks ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire